PR95380

EAST RUTHERFORD, N.J., April 13, 2022 /PRNewswire=KYODO JBN/ --

Cambrex announced today the completion of a $50 million expansion of its

large-scale active pharmaceutical ingredient (API) manufacturing capabilities

at its Charles City, Iowa facility. The startup of the new manufacturing space

is the culmination of a two-year project, originally announced in 2020, to

increase the capacity of Cambrex's flagship API facility by 30%. The expansion

positions Cambrex with the largest and most advanced API facility in the United

States and ensures the long-term capacity to support Cambrex's existing

customer base and future growth supported by robust market demand.

"The opening of our Charles City facility expansion is a significant milestone

for Cambrex, solidifying our position as the leading U.S.-based provider of

small molecule APIs," said Thomas Loewald, CEO of Cambrex. "We continue to see

strong demand for high quality, U.S.-based development, and manufacturing of

new APIs, and we are excited to offer our existing and potential new customers

access to the best-in-class capabilities of our Charles City facility."

Following the expansion, Cambrex's Charles City facility has approximately 400

employees and an installed reactor capacity of over 25,000 gallons

(approximately 100 cubic meters). With multiple large-scale manufacturing

areas, the facility is able to reduce production timelines by manufacturing

multiple products with complex chemical syntheses in parallel. The facility is

located on a 45-acre property and produces a wide range of APIs and

pharmaceutical intermediates, including highly potent molecules and controlled

substances.

In addition to its expansion in Iowa, Cambrex continues to invest in additional

small- and mid-scale API manufacturing capacity at its Karlskoga, Sweden, and

High Point, North Carolina facilities. New capacity at those facilities is

expected to come online in late 2022 and mid-2023, respectively.

About Cambrex

Cambrex is a leading global contract development and manufacturing organization

(CDMO) that provides drug substance, drug product, and analytical services

across the entire drug lifecycle. With over 40 years of experience and a

growing team of over 2,200 experts servicing global clients from North America

and Europe, Cambrex is a trusted partner in branded and generic markets for API

and finished dosage form development and manufacturing.

Cambrex offers a range of specialized drug substance technologies and

capabilities, including biocatalysis, continuous flow, controlled substances,

solid-state science, material characterization, and highly potent APIs. In

addition, Cambrex can support conventional dosage forms, including oral solids,

semi-solids, and liquids, and has the expertise to manufacture specialty dosage

forms such as modified-release, fixed-dose combination, pediatric, bi-layer

tablets, stick packs, topicals, controlled substances, sterile, and non-sterile

ointments.

For more information, visit www.cambrex.com　

Logo - https://mma.prnewswire.com/media/1723116/Cambrex_40_Years_Logo.jpg

SOURCE: Cambrex